Inovio Pharmaceuticals Net Worth
Inovio Pharmaceuticals Net Worth Breakdown | INO |
Inovio Pharmaceuticals Net Worth Analysis
Inovio Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Inovio Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Inovio Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Inovio Pharmaceuticals' net worth analysis. One common approach is to calculate Inovio Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Inovio Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Inovio Pharmaceuticals' net worth. This approach calculates the present value of Inovio Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Inovio Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Inovio Pharmaceuticals' net worth. This involves comparing Inovio Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Inovio Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Inovio Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Inovio Pharmaceuticals' net worth research are outlined below:
| Inovio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Inovio Pharmaceuticals has high historical volatility and very poor performance | |
| Inovio Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 832.01 K. Reported Net Loss for the year was (135.12 M) with loss before taxes, overhead, and interest of (177.39 M). | |
| Inovio Pharmaceuticals has about 348.13 M in cash with (124.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4. | |
| Inovio Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Inovio Pharmaceuticals SWOT analysis stock faces challenges amid pipeline progress |
Inovio Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Inovio Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Inovio Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Inovio Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Inovio Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inovio Pharmaceuticals backward and forwards among themselves. Inovio Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Inovio Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Qube Research & Technologies | 2024-06-30 | 79.3 K | Deerfield Management Co | 2024-09-30 | 76.5 K | Charles Schwab Investment Management Inc | 2024-09-30 | 71.1 K | Nuveen Asset Management, Llc | 2024-06-30 | 46.5 K | Goldman Sachs Group Inc | 2024-06-30 | 42.4 K | American Century Companies Inc | 2024-09-30 | 40.8 K | Rhumbline Advisers | 2024-06-30 | 38.5 K | Bank Of America Corp | 2024-06-30 | 38.4 K | Green Alpha Advisors, Llc | 2024-09-30 | 32.2 K | Deep Track Capital, Lp | 2024-09-30 | 1.8 M | Vanguard Group Inc | 2024-09-30 | 1.8 M |
Follow Inovio Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 104.66 M.Market Cap |
|
Project Inovio Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (1.04) | (1.09) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (1.15) | (1.21) |
When accessing Inovio Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Inovio Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Inovio Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Inovio Pharmaceuticals' management efficiency
Inovio Pharmaceuticals has Return on Asset of (0.3991) % which means that on every $100 spent on assets, it lost $0.3991. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.9142) %, meaning that it generated no profit with money invested by stockholders. Inovio Pharmaceuticals' management efficiency ratios could be used to measure how well Inovio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.82. In addition to that, Return On Capital Employed is likely to drop to -1.09. At this time, Inovio Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 27th of November 2024, Other Current Assets is likely to grow to about 6.9 M, while Total Assets are likely to drop about 131.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.29 | 4.28 | |
| Tangible Book Value Per Share | 5.29 | 3.73 | |
| Enterprise Value Over EBITDA | (1.16) | (1.22) | |
| Price Book Value Ratio | 1.16 | 1.10 | |
| Enterprise Value Multiple | (1.16) | (1.22) | |
| Price Fair Value | 1.16 | 1.10 | |
| Enterprise Value | 322.2 M | 306.1 M |
Leadership effectiveness at Inovio Pharmaceuticals is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 174.195 | Revenue 591.9 K | Quarterly Revenue Growth (0.55) | Revenue Per Share 0.025 | Return On Equity (0.91) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inovio Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inovio Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inovio Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Inovio Pharmaceuticals Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 13th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 1st of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Inovio Pharmaceuticals Earnings per Share Projection vs Actual
Inovio Pharmaceuticals Corporate Management
| Asli Gevgilili | Chief Officer | Profile | |
| Jeffrey Skolnik | Senior Development | Profile | |
| Robert Juba | Senior Management | Profile | |
| E MBA | Senior Assurance | Profile | |
| MBA MA | Senior Development | Profile | |
| Ben Matone | Director Relations | Profile | |
| Laurent Humeau | Chief Scientific Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.